Description

when did they stop vaccinating for polio ?

When Did They Stop Vaccinating for Polio?

When it comes to the history of vaccination strategies, the eradication and vaccination practices for polio hold a particularly significant place in medical history. Few people today experience the paralyzing effects of polio, yet the fear and impact of polio outbreaks in the past have left a lasting impact on the public health system around the world.

### The Vaccine Transition in the United States

The U.S. used the oral polio vaccine (OPV), developed by Dr. Albert Sabin, for several years. This type of vaccine uses a weakened version of the live virus to elicit an immune response without causing the disease. However, in 2000, the U.S. switched completely to the inactivated polio vaccine (IPV), which uses a killed version of the virus to prevent polio and is administered via injection. The decision to switch from OPV to IPV was made due to the fact that IPV is safer, as it does not carry the remote risk of the virus reverting to a paralytic form that can occur with the live OPV.

### The Eradication Progress Worldwide

The eradication of polio has been a global effort with remarkable achievements. In 1994, polio was declared eliminated from the Western Hemisphere due to the diligent use of both OPV and IPV. By 2000, the Western Pacific region, which includes countries such as Australia, ended their use of OPV and solely relied on IPV. As of 2003, polio endemic countries were significantly reduced to six and by 2006, only four remained. The global fight against polio continues to this day, but the impact of the vaccination programs has reduced the number of annual cases to only a handful.

### History of Polio Vaccines

Vaccination against polio has a long and storied history leading back to the creation of the first polio vaccines:

– In 1955, Jonas Salk introduced the inactivated polio vaccine (IPV), which was administered through a series of shots.
– Then, in 1961, Dr. Albert Sabin developed the oral polio vaccine (OPV). This version was favored for its ease of administration and its ability to provide long-term immunity.
– While OPV is still used in some countries, many others, including the U.S., have phased it out due to considerations of safety and efficacy in countries where polio has been eradicated. Today, the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend the continued use of IPV to maintain eradication, and to ensure that new generations are protected from the disease.

### Continuing Polio Prevention

Despite decades of global effort, polio remains on the eradication radar. The CDC and WHO continue to emphasize the importance of polio vaccination, particularly with IPV. The goal of eliminating polio from the last remaining endemic countries not only ensures that these populations stay protected but also prevents the disease from repopulating areas from where it has been eliminated.

The shift from live virus oral polio vaccine to inactivated polio vaccine continues to be a part of the broader public health strategy in the U.S. The IPV is now administered in the U.S., with a recommended series of four doses given at the ages of 2 months, 4 months, between 6 and 18 months, and a final booster dose at 4 through 6 years. This schedule is designed to ensure each individual has developed strong long-term immune responses to prevent an outbreak if the virus were to ever re-emerge.

### Conclusion

The progression from OPV to IPV represents a step forward in the way we protect against polio. While the U.S. phased out the oral polio vaccine years ago, the ongoing management of this vaccine is a testament to the enduring commitment to global health and the continual improvement of public health strategies. The history of polio vaccination is a testament to the power of science and the concerted effort of health authorities worldwide to keep communities safe from this hazardous disease. As long as polio remains a threat in any part of the world, the need for continued vaccination and monitoring remains crucial in defending against the resurgence of this debilitating illness.